SPDL1 and neoplasm: It is demonstrated that the plasma concentrations of sPD-1, sPD-L1, and/or sCTLA-4 were higher than those of healthy donors, with some differences according to tumour types, implying that anti-tumour immunity has launched in tumour bearing patients.